John L Wallace

List of Publications by Year in Descending Order

239 papers	21,598 citations	76 h-index	140 g-index
245 ext. papers	23,105 ext. citations	6.9 avg, IF	7.05 L-index

#	Paper	IF	Citations
239	Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology. *Frontiers in Pharmacology*, **2021**, 12, 657457	5.6	5
238	Microbiome Profile and Molecular Pathways Alterations in Gastrointestinal Tract by Hydrogen Sulfide-Releasing Nonsteroidal Anti-Inflammatory Drug (ATB-352): Insight into Possible Safer Polypharmacy. *Antioxidants and Redox Signaling*, **2021**,	8.4	3
237	Effects of Hydrogen Sulfide on the Microbiome: From Toxicity to Therapy. *Antioxidants and Redox Signaling*, **2021**,	8.4	12
236	Comment on "Evidence that the ProPerDP method is inadequate for protein persulfidation detection due to lack of specificity". *Science Advances*, **2021**, 7,	14.3	2
235	Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation. *Journal of Crohn's and Colitis*, **2021**, 15, 787-799	1.5	10
234	Potent anti-inflammatory effects of an H S-releasing naproxen (ATB-346) in a human model of inflammation. *FASEB Journal*, **2021**, 35, e21913	0.9	1
233	Gastrointestinal biofilms in health and disease. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 314-334	24.2	42
232	Enhanced Analgesic Effects and Gastrointestinal Safety of a Novel, Hydrogen Sulfide-Releasing Anti-Inflammatory Drug (ATB-352): A Role for Endogenous Cannabinoids. *Antioxidants and Redox Signaling*, **2020**, 33, 1003-1009	8.4	13
231	Giardia spp. promote the production of antimicrobial peptides and attenuate disease severity induced by attaching and effacing enteropathogens via the induction of the NLRP3 inflammasome. *International Journal for Parasitology*, **2020**, 50, 263-275	4.3	14
230	A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug. *British Journal of Pharmacology*, **2020**, 177, 769-777	8.6	44
229	Active thrombin produced by the intestinal epithelium controls mucosal biofilms. *Nature Communications*, **2019**, 10, 3224	17.4	22
228	Efficacy of a Peruvian Botanical Remedy (Sabell A4+) for Treating Liver Disease and Protecting Gastric Mucosal Integrity. *Evidence-based Complementary and Alternative Medicine*, **2019**, 2019, 5486728	2.3	
227	Effect of Ketoprofen and ATB-352 on the Immature Human Intestine: Identification of Responders and Non-responders. *Journal of Pediatric Gastroenterology and Nutrition*, **2019**, 68, 623-629	2.8	3
226	Nitric oxide in the gastrointestinal tract: opportunities for drug development. *British Journal of Pharmacology*, **2019**, 176, 147-154	8.6	26
225	Eicosanoids in the gastrointestinal tract. *British Journal of Pharmacology*, **2019**, 176, 1000-1008	8.6	23
224	Anti-inflammatory effect of ATB-352, a H2S -releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats. *Pharmacological Research*, **2018**, 132, 220-231	10.2	37
223	Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic. *Antioxidants and Redox Signaling*, **2018**, 28, 1533-1540	8.4	70

222	Hydrogen sulfide: an agent of stability at the microbiome-mucosa interface. *American Journal of Physiology - Renal Physiology*, **2018**, 314, G143-G149	5.1	56
221	NSAID-Induced Gastrointestinal Damage and the Design of GI-Sparing NSAIDs. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, CL-24	0	1
220	Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2018**, 24, 1493-1502	4.5	20
219	Giardia duodenalis induces pathogenic dysbiosis of human intestinal microbiota biofilms. *International Journal for Parasitology*, **2017**, 47, 311-326	4.3	94
218	Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury. *Digestive Diseases and Sciences*, **2017**, 62, 2223-2230	4	32
217	Trends in development of gi-safe anti-inflammatory drugs. *Klinicheskaia Meditsina*, **2017**, 95, 222-227	0.2	0
216	ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo. *Pharmacological Research*, **2016**, 114, 67-73	10.2	42
215	Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-B and NFAT transcriptional pathways. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 434-9	11.5	112
214	Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis. *PLoS ONE*, **2016**, 11, e0147289	3.7	17
213	Hydrogen sulfide-releasing anti-inflammatory drugs for chemoprevention and treatment of cancer. *Pharmacological Research*, **2016**, 111, 652-658	10.2	20
212	Anti-inflammatory and cytoprotective properties of hydrogen sulfide. *Methods in Enzymology*, **2015**, 555, 169-93	1.7	36
211	Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction. *Inflammopharmacology*, **2015**, 23, 91-9	5.1	4
210	Gaseous mediators in resolution of inflammation. *Seminars in Immunology*, **2015**, 27, 227-33	10.7	70
209	Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. *American Journal of Physiology - Renal Physiology*, **2015**, 308, G994-1003	5.1	33
208	NSAID enteropathy and bacteria: a complicated relationship. *Journal of Gastroenterology*, **2015**, 50, 387-93	6.9	52
207	Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. *Nature Reviews Drug Discovery*, **2015**, 14, 329-45	64.1	482
206	Interactions of hydrogen sulfide with myeloperoxidase. *British Journal of Pharmacology*, **2015**, 172, 1516-32	6.8	75
205	Toward More GI-Friendly Anti-Inflammatory Medications. *Current Treatment Options in Gastroenterology*, **2015**, 13, 377-85	2.5	6

204	Gaseous mediator-based anti-inflammatory drugs. *Current Opinion in Pharmacology*, **2015**, 25, 1-6	5.1	12
203	Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. *British Journal of Pharmacology*, **2015**, 172, 992-1004	8.6	45
202	Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. *Antioxidants and Redox Signaling*, **2015**, 22, 398-410	8.4	94
201	Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. *Inflammatory Bowel Diseases*, **2015**, 21, 1006-17	4.5	106
200	Proresolution effects of hydrogen sulfide during colitis are mediated through hypoxia-inducible factor-1 *FASEB Journal*, **2015**, 29, 1591-602	0.9	39
199	H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventative potential. *Nitric Oxide - Biology and Chemistry*, **2015**, 46, 25-31	5	60
198	Endogenous prostaglandins and afferent sensory nerves in gastroprotective effect of hydrogen sulfide against stress-induced gastric lesions. *PLoS ONE*, **2015**, 10, e0118972	3.7	36
197	Hydrogen sulfide-based anti-inflammatory and chemopreventive therapies: an experimental approach. *Current Pharmaceutical Design*, **2015**, 21, 3012-22	3.3	13
196	Environmental and NSAID-enteropathy: dysbiosis as a common factor. *Current Gastroenterology Reports*, **2014**, 16, 377	5	14
195	Exploiting endogenous anti-inflammatory pathways as a therapeutic approach to multiorgan inflammatory disease. *American Journal of Pathology*, **2014**, 184, 2154-5	5.8	1
194	Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage. *Stress*, **2014**, 17, 528-37	3	16
193	NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. *Current Opinion in Pharmacology*, **2014**, 19, 11-6	5.1	51
192	Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. *Nitric Oxide - Biology and Chemistry*, **2014**, 41, 131-7	5	37
191	Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice. *Journal of Neuroinflammation*, **2014**, 11, 196	10.1	28
190	Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 13559-64	11.5	66
189	Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. *PLoS ONE*, **2014**, 9, e110688	3.7	24
188	Polypharmacy of osteoarthritis: the perfect intestinal storm. *Digestive Diseases and Sciences*, **2013**, 58, 3088-93	4	34
187	A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. *Medical Gas Research*, **2013**, 3, 24	2.2	25

186	Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. *American Journal of Physiology - Renal Physiology*, **2013**, 305, G467-73	5.1	67
185	Hydrogen sulfide inhibits oxidative stress in lungs from allergic mice in vivo. *European Journal of Pharmacology*, **2013**, 698, 463-9	5.3	51
184	Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. *World Journal of Gastroenterology*, **2013**, 19, 1861-76	5.6	125
183	A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. *FASEB Journal*, **2013**, 27, 4489-99	0.9	33
182	Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. *PLoS ONE*, **2013**, 8, e71962	3.7	50
181	Hydrogen Sulfide: Its Production, Release and Functions **2013**, 109-125		2
180	Su1724 Bifidobacteria Exert a Protective Effect Against NSAID-Induced Enteropathy That is Dependent on Lactate Production. *Gastroenterology*, **2012**, 142, S-489	13.3	5
179	Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. *PLoS ONE*, **2012**, 7, e39244	3.7	59
178	Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. *Antioxidants and Redox Signaling*, **2012**, 17, 58-67	8.4	153
177	NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. *British Journal of Pharmacology*, **2012**, 165, 67-74	8.6	104
176	Hydrogen sulfide and resolution of acute inflammation: A comparative study utilizing a novel fluorescent probe. *Scientific Reports*, **2012**, 2, 499	4.9	70
175	Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. *PLoS ONE*, **2012**, 7, e35196	3.7	72
174	Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. *Gastroenterology*, **2011**, 141, 1314-22, 1322.e1-5	13.3	318
173	Muc-2-deficient mice display a sex-specific, COX-2-related impairment of gastric mucosal repair. *American Journal of Pathology*, **2011**, 178, 1126-33	5.8	20
172	Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. *American Journal of Physiology - Renal Physiology*, **2011**, 301, G188-93	5.1	51
171	Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). *British Journal of Pharmacology*, **2010**, 159, 1236-46	8.6	160
170	A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 12023-7	11.5	63
169	New pharmacologic therapies in gastrointestinal disease. *Gastroenterology Clinics of North America*, **2010**, 39, 709-20	4.4	15

168	Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. *Antioxidants and Redox Signaling*, **2010**, 12, 1125-33	8.4	99
167	Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. *Journal of Medicinal Chemistry*, **2010**, 53, 6275-86	8.3	213
166	Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. *Digestive and Liver Disease*, **2010**, 42, 103-9	3.3	77
165	Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. *Trends in Pharmacological Sciences*, **2009**, 30, 112-7	13.2	49
164	Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. *Gastroenterology*, **2009**, 137, 569-78, 578.e1	13.3	214
163	Resolution of mucosal inflammation **2008**, 223-234		
162	Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. *Physiological Reviews*, **2008**, 88, 1547-65	47.9	437
161	Annexin-1 modulates repair of gastric mucosal injury. *American Journal of Physiology - Renal Physiology*, **2008**, 294, G764-9	5.1	45
160	A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner. *American Journal of Physiology - Renal Physiology*, **2008**, 295, G374-81	5.1	26
159	NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. *Current Opinion in Investigational Drugs*, **2008**, 9, 1151-6		38
158	Resolution of inflammation: state of the art, definitions and terms. *FASEB Journal*, **2007**, 21, 325-32	0.9	821
157	Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. *Gastroenterology*, **2007**, 132, 261-71	13.3	218
156	Hydrogen sulfide enhances ulcer healing in rats. *FASEB Journal*, **2007**, 21, 4070-6	0.9	178
155	Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H3636-42	5.2	5
154	Hydrogen sulfide-releasing anti-inflammatory drugs. *Trends in Pharmacological Sciences*, **2007**, 28, 501-5	13.2	242
153	A Hydrogen-Sulfide Releasing Derivative of Mesalamine Exhibits Markedly Enhanced Anti-Inflammatory Effects in Experimental Colitis. *FASEB Journal*, **2007**, 21, A131	0.9	
152	Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection. *Inflammation and Allergy: Drug Targets*, **2006**, 5, 133-7		37
151	Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 325-35	4.7	214

150	Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB Journal*, **2006**, 20, 2118-20	0.9	676
149	Commonality of defensive roles of COX-2 in the lung and gut. *American Journal of Pathology*, **2006**, 168, 1060-3	5.8	9
148	The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. *Gastroenterology*, **2006**, 131, 259-71	13.3	311
147	5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 319, 447-58	4.7	116
146	COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. *Scientific World Journal, The*, **2006**, 6, 577-88	2.2	62
145	Gastrointestinal inflammation: a central component of mucosal defense and repair. *Experimental Biology and Medicine*, **2006**, 231, 130-7	3.7	99
144	Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor. *British Journal of Pharmacology*, **2006**, 148, 274-8	8.6	28
143	Recent advances in gastric ulcer therapeutics. *Current Opinion in Pharmacology*, **2005**, 5, 573-7	5.1	56
142	Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. *American Journal of Pathology*, **2005**, 167, 1293-300	5.8	36
141	Lipoxins in gastric mucosal health and disease. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2005**, 73, 251-5	2.8	11
140	Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. *Gastroenterology*, **2005**, 129, 1210-24	13.3	331
139	Nitric oxide as a regulator of inflammatory processes. *Memorias Do Instituto Oswaldo Cruz*, **2005**, 100 Suppl 1, 5-9	2.6	89
138	Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. *Experimental Biology and Medicine*, **2005**, 230, 255-62	3.7	54
137	Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. *British Journal of Pharmacology*, **2005**, 145, 275-82	8.6	112
136	Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow. *British Journal of Pharmacology*, **2005**, 146, 481-6	8.6	32
135	Roles of platelets and proteinase-activated receptors in gastric ulcer healing. *Digestive Diseases and Sciences*, **2005**, 50 Suppl 1, S12-5	4	20
134	Annexin-1 is an endogenous gastroprotective factor against indomethacin-induced damage. *American Journal of Physiology - Renal Physiology*, **2005**, 288, G481-6	5.1	10
133	Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 216-20	11.5	232

132	Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. *American Journal of Physiology - Renal Physiology*, **2004**, 286, G76-81	5.1	39
131	Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. *Canadian Journal of Gastroenterology & Hepatology*, **2004**, 18, 229-36		38
130	Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 1096-102	4.7	18
129	Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 626-33	4.7	24
128	Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. *Circulation*, **2004**, 110, 1320-5	16.7	44
127	Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. *Journal of Pharmacology and Experimental Therapeutics*,	4.7	40
126	A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 15736-41	11.5	139
125	Acetaminophen hepatotoxicity: NO to the rescue. *British Journal of Pharmacology*, **2004**, 143, 1-2	8.6	32
124	Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. *British Journal of Pharmacology*, **2004**, 143, 618-25	8.6	30
123	A protease activated receptor-2 (PAR-2) activating peptide, tc-LIGRLO-NH2, induces protease release from mast cells: role in TNF degradation. *BMC Pharmacology*, **2004**, 4, 12		18
122	A role for proteinase-activated receptor-1 in inflammatory bowel diseases. *Journal of Clinical Investigation*, **2004**, 114, 1444-56	15.9	65
121	The vascular endothelium and nitric oxide **2004**, 13-18		
120	Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 10937-41	11.5	109
119	Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 11104-9	11.5	114
118	Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. *American Journal of Physiology - Renal Physiology*, **2003**, 285, G54-61	5.1	39
117	Proteinase-activated receptors (PARs), platelets and angiogenesis. *Drug Development Research*, **2003**, 59, 395-399	5.1	1
116	The therapeutic potential of NO-NSAIDs. *Fundamental and Clinical Pharmacology*, **2003**, 17, 11-20	3.1	127
115	Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat. *British Journal of Pharmacology*, **2003**, 139, 966-72	8.6	21

114	Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. *FASEB Journal*, **2003**, 17, 1171-3	0.9	59
113	A magic bullet for mucosal protection...and aspirin is the trigger!. *Trends in Pharmacological Sciences*, **2003**, 24, 323-6	13.2	48
112	Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. *Canadian Journal of Physiology and Pharmacology*, **2003**, 81, 920-7	2.4	76
111	Mucosal repair and COX-2 inhibition. *Current Pharmaceutical Design*, **2003**, 9, 2207-11	3.3	26
110	Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 282, H2004-10	5.2	26
109	Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. *Journal of Neuroscience*, **2002**, 22, 2246-54	6.6	327
108	Potential cardioprotective actions of no-releasing aspirin. *Nature Reviews Drug Discovery*, **2002**, 1, 375-82	64.1	115
107	A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. *British Journal of Pharmacology*, **2002**, 135, 589-99	8.6	27
106	Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. *British Journal of Pharmacology*, **2002**, 135, 1540-6	8.6	29
105	Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 302, 466-74	4.7	60
104	Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 13243-7	11.5	118
103	Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 1689-94	11.5	69
102	Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. *American Journal of Pathology*, **2002**, 161, 1903-15	5.8	311
101	Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. *Gastroenterology*, **2002**, 123, 1598-606	13.3	120
100	Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. *Blood*, **2002**, 100, 1160-1167	2.2	486
99	Inflammatory mediators in gastrointestinal defense and injury. *Experimental Biology and Medicine*, **2001**, 226, 1003-15	3.7	87
98	Inhibition of neurogenic inflammation by the Amazonian herbal medicine sangre de grado. *Journal of Investigative Dermatology*, **2001**, 117, 725-30	4.3	24
97	Pathogenesis of NSAID-induced gastroduodenal mucosal injury. *Bailliere's Best Practice and Research in Clinical Gastroenterology*, **2001**, 15, 691-703	2.5	113

96	Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. *British Journal of Pharmacology*, **2001**, 133, 975-87	8.6	108
95	Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. *British Journal of Pharmacology*, **2001**, 133, 1314-22	8.6	49
94	Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. *British Journal of Pharmacology*, **2001**, 134, 701-4	8.6	41
93	Inhibition of attaching and effacing lesion formation following enteropathogenic Escherichia coli and Shiga toxin-producing E. coli infection. *Infection and Immunity*, **2001**, 69, 7152-8	3.7	16
92	Prostaglandin biology in inflammatory bowel disease. *Gastroenterology Clinics of North America*, **2001**, 30, 971-80	4.4	82
91	Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Mechanisms of protection and healing: current knowledge and future research. *American Journal of Medicine*, **2001**, 110, 19S-23S	2.4	81
90	Protease-activated receptors in inflammation, neuronal signaling and pain. *Trends in Pharmacological Sciences*, **2001**, 22, 146-52	13.2	327
89	NO-mesalamine protects colonic epithelial cells against apoptotic damage induced by proinflammatory cytokines. *American Journal of Physiology - Renal Physiology*, **2001**, 281, G654-65	5.1	13
88	Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. *American Journal of Physiology - Renal Physiology*, **2001**, 281, G635-44	5.1	59
87	GI and Cardiovascular Profiles of New NSAIDs: Selective COX-2 Inhibitors and NO-NSAIDs. *Medical Science Symposia Series*, **2001**, 163-169		2
86	Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. *British Journal of Pharmacology*, **2000**, 129, 681-6	8.6	85
85	Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. *British Journal of Pharmacology*, **2000**, 129, 1423-30	8.6	94
84	NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund© adjuvant arthritis. *British Journal of Pharmacology*, **2000**, 130, 1399-405	8.6	69
83	How do NSAIDs cause ulcer disease?. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2000**, 14, 147-59	2.5	61
82	Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. *American Journal of Physiology - Renal Physiology*, **2000**, 279, G238-44	5.1	119
81	Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. *American Journal of Physiology - Renal Physiology*, **2000**, 279, G341-6	5.1	68
80	Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach. *American Journal of Physiology - Renal Physiology*, **2000**, 279, G1292-7	5.1	33
79	Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H528-35	5.2	27

78	NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. *Gastroenterology*, **2000**, 119, 706-14	13.3	555
77	Nitric oxide in mucosal defense: a little goes a long way. *Gastroenterology*, **2000**, 119, 512-20	13.3	330
76	The Arachidonic Acid Pathway **2000**, 1-20		
75	Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. *American Journal of Physiology - Renal Physiology*, **1999**, 276, G1313-6	5.1	62
74	Prolonged colonic epithelial hyporesponsiveness after colitis: role of inducible nitric oxide synthase. *American Journal of Physiology - Renal Physiology*, **1999**, 276, G703-10	5.1	50
73	Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release. *American Journal of Physiology - Renal Physiology*, **1999**, 277, G847-54	5.1	24
72	Pathogenesis of nonsteroidal anti-inflammatory drug gastropathy: clues to preventative therapy. *Canadian Journal of Gastroenterology & Hepatology*, **1999**, 13, 123-7		8
71	Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). *British Journal of Pharmacology*, **1999**, 126, 1262-8	8.6	98
70	Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. *British Journal of Pharmacology*, **1999**, 126, 1200-4	8.6	100
69	Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. *British Journal of Pharmacology*, **1999**, 127, 1083-90	8.6	183
68	Synthesis and analgesic activity of 2-methyl-2-[1-(3-benzoyl-4-substituted-1,4-dihydropyridyl)]acetic acid methyl esters, acetic acids, and acetamides. *Archiv Der Pharmazie*, **1999**, 332, 213-8	4.3	4
67	Selective COX-2 inhibitors: is the water becoming muddy?. *Trends in Pharmacological Sciences*, **1999**, 20, 4-6	13.2	69
66	In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. *Thrombosis Research*, **1999**, 93, 43-50	8.2	77
65	Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. *Gastroenterology*, **1999**, 117, 557-66	13.3	79
64	Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). *American Journal of Medicine*, **1999**, 107, 11S-16S; discussion 16S-17S	2.4	77
63	Nitric oxide: a regulator of mucosal defense and injury. *Journal of Gastroenterology*, **1998**, 33, 792-803	6.9	69
62	Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. *Life Sciences*, **1998**, 62, PL235-40	6.8	47
61	Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. *Life Sciences*, **1998**, 62, PL 367-73	6.8	93

60	Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. *Gastroenterology*, **1998**, 115, 101-9	13.3	266
59	Effects of R- and S-enantiomers of chiral non-steroidal anti-inflammatory drugs in experimental colitis. *Journal of Gastroenterology and Hepatology (Australia)*, **1998**, 13, S266-S269	4	
58	Neutrophil-mediated gastrointestinal injury. *Canadian Journal of Gastroenterology & Hepatology*, **1998**, 12, 559-68		54
57	Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. *American Journal of Physiology - Renal Physiology*, **1998**, 275, G425-32	5.1	46
56	Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe?. *Journal of Clinical Gastroenterology*, **1998**, 27 Suppl 1, S28-34	3	42
55	Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a new generation of antithrombotics?. *Expert Opinion on Investigational Drugs*, **1997**, 6, 533-8	5.9	4
54	Inflammatory bowel disorders: current and future drugs that modulate adhesion molecules. *BioDrugs*, **1997**, 7, 273-84	7.9	1
53	Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. *American Journal of Physiology - Renal Physiology*, **1997**, 273, G1246-51	5.1	30
52	Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. *Journal of Gastroenterology*, **1997**, 32, 127-33	6.9	53
51	Gastrointestinal-sparing anti-inflammatory drugs: The development of nitric oxide-releasing NSAIDs **1997**, 42, 144-149		29
50	Underlying mechanisms of portal hypertensive gastropathy. *Journal of Clinical Gastroenterology*, **1997**, 25 Suppl 1, S73-8	3	25
49	Selective inhibitors of cyclooxygenase-2. Potential in elderly patients. *Drugs and Aging*, **1996**, 9, 406-17	4.7	11
48	The cellular and molecular basis of gastric mucosal defense. *FASEB Journal*, **1996**, 10, 731-40	0.9	271
47	Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. *Journal of Pharmacological and Toxicological Methods*, **1995**, 33, 237-9	1.7	75
46	Nitric oxide as a mediator of gastrointestinal mucosal injury?-Say it ain't so. *Mediators of Inflammation*, **1995**, 4, 397-405	4.3	44
45	Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester. *European Journal of Pharmacology*, **1995**, 280, 63-8	5.3	32
44	Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. *Gastroenterology*, **1995**, 108, 1183-91	13.3	43
43	A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. *Gastroenterology*, **1995**, 109, 524-30	13.3	210

42	Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. *Gastroenterology*, **1995**, 109, 1173-80	13.3	87
41	Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Development of NSAIDs with reduced gastrointestinal and renal toxicity. *Expert Opinion on Investigational Drugs*, **1995**, 4, 613-619	5.9	4
40	Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. *Agents and Actions Supplements*, **1995**, 46, 121-9	0.2	12
39	The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage--potential for development of gastrointestinal tract safe NSAIDs. *Canadian Journal of Physiology and Pharmacology*, **1994**, 72, 1493-8	2.4	76
38	A diclofenac derivative without ulcerogenic properties. *European Journal of Pharmacology*, **1994**, 257, 249-55	5.3	123
37	Markedly reduced intestinal toxicity of a diclofenac derivative. *Life Sciences*, **1994**, 55, PL1-8	6.8	43
36	Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. *Gastroenterology*, **1994**, 107, 173-9	13.3	260
35	Characterization of a simple animal model for nonsteroidal anti-inflammatory drug induced antral ulcer. *Canadian Journal of Physiology and Pharmacology*, **1993**, 71, 447-52	2.4	21
34	Gastric ulceration: critical events at the neutrophil--endothelium interface. *Canadian Journal of Physiology and Pharmacology*, **1993**, 71, 98-102	2.4	66
33	Prostaglandins inhibit inflammatory mediator release from rat mast cells. *Gastroenterology*, **1993**, 104, 122-9	13.3	99
32	Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy?. *Gastroenterology*, **1993**, 105, 1630-6	13.3	69
31	Inflammatory Mediators in Inflammatory Bowel Disease: Clues for Designer Therapy. *Canadian Journal of Gastroenterology & Hepatology*, **1993**, 7, 121-126		
30	Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. *Gastroenterology*, **1992**, 102, 18-27	13.3	138
29	Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. *Gastroenterology*, **1992**, 102, 1176-1185	13.3	38
28	Immunopathology of NSAID-gastropathy: inhibitory effects of interleukin-I and cyclosporin A. *Annals of the New York Academy of Sciences*, **1992**, 664, 400-7	6.5	7
27	Pathogenesis of NSAID gastropathy: are neutrophils the culprits?. *Trends in Pharmacological Sciences*, **1992**, 13, 129-31	13.2	112
26	Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. *Inflammation*, **1992**, 16, 343-54	5.1	64
25	Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. *Inflammation*, **1992**, 16, 227-40	5.1	60

24	A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. *Gastroenterology*, **1991**, 100, 878-83	13.3	251
23	Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. *Gastroenterology*, **1990**, 98, 1178-86	13.3	61
22	The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. *Gastroenterology*, **1990**, 99, 295-304	13.3	81
21	Leukotriene B4 potentiates colonic ulceration in the rat. *Digestive Diseases and Sciences*, **1990**, 35, 622-9	4	45
20	Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1 beta. *European Journal of Pharmacology*, **1990**, 186, 279-84	5.3	35
19	Alterations in regional blood flow in rats following sensitization to the nematode Nippostrongylus brasiliensis: effects of PAF antagonists. *British Journal of Pharmacology*, **1990**, 101, 93-6	8.6	5
18	Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. *Life Sciences*, **1989**, 45, 1869-76	6.8	173
17	Hapten-induced model of chronic inflammation and ulceration in the rat colon. *Gastroenterology*, **1989**, 96, 795-803	13.3	639
16	Hapten-Induced Model of Chronic Inflammation and Ulceration in the Rat Colon. *Gastroenterology*, **1989**, 96, 795-803	13.3	1239
15	Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. *Gastroenterology*, **1989**, 96, 29-36	13.3	372
14	Gastrointestinal damage induced by platelet-activating factor. Inhibition by the corticoid, dexamethasone. *Digestive Diseases and Sciences*, **1988**, 33, 225-32	4	12
13	Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. *Canadian Journal of Physiology and Pharmacology*, **1988**, 66, 422-5	2.4	63
12	Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. *Gastroenterology*, **1987**, 93, 765-73	13.3	169
11	Failure of prostaglandin E2 and its 16,16-dimethyl analogue to prevent the gastric mucosal damage induced by Paf. *British Journal of Pharmacology*, **1987**, 90, 365-71	8.6	14
10	Potent ulcerogenic actions of platelet-activating factor on the stomach. *Nature*, **1986**, 319, 54-6	50.4	229
9	Prevention of endotoxin-induced gastrointestinal damage by CV-3988, an antagonist of platelet-activating factor. *European Journal of Pharmacology*, **1986**, 124, 209-10	5.3	56
8	Effects of inhibitors of arachidonic acid metabolism on Paf-induced gastric mucosal necrosis and haemoconcentration. *British Journal of Pharmacology*, **1986**, 89, 415-22	8.6	36
7	Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. *Prostaglandins*, **1986**, 31, 989-98		61

6	Role of mucus in the repair of gastric epithelial damage in the rat. Inhibition of epithelial recovery by mucolytic agents. *Gastroenterology*, **1986**, 91, 603-11	13.3	141
5	Acceleration of recovery of gastric epithelial integrity by 16,16-dimethyl prostaglandin E2. *British Journal of Pharmacology*, **1985**, 86, 837-42	8.6	16
4	Role of prostanoids in the protective actions of BW755C on the gastric mucosa. *European Journal of Pharmacology*, **1985**, 115, 45-52	5.3	57
3	Reduction by cytoprotective agents of ethanol-induced damage to the rat gastric mucosa: a correlated morphological and physiological study. *Canadian Journal of Physiology and Pharmacology* , **1982**, 60, 1686-99	2.4	96
2	The roles of ethanol and of acid in the production of gastric mucosal erosions in rats. *Vigiliae Christianae*, **1981**, 38, 23-38	0.2	121
1	Gastrointestinal Inflammation and Ulceration: Mediators of Induction and Resolution282-298		